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a b s t r a c t
This study aimed to evaluate the methylation levels of G protein-coupled receptor (GPCR) related genes
and the effects of methylation on mRNA expression levels in aldosterone-producing adenoma (APA). DNA
methylation array and transcriptome analysis were applied in non-functioning adrenocortical adenoma
(NFA) and APA. We investigated 192 GPCR-related genes and found hypo-methylation in the promoter
region of 66 of these genes in APA. An integration study between microarray and methylation analysis
revealed that HTR4, MC2R, TACR1, GRM3, and PTGER1 showed hypo-methylation and up-regulation of
mRNA in APA. qPCR analysis showed that HTR4 and PTGER1 expression was 9.3-fold and 6.6-fold higher
in APAs than in NFAs, respectively, whereas expression of the other genes was not different between the
groups. Methylation of HTR4 and PTGER1 at positions !229 and !666 from the transcription start site,
respectively, showed a signiﬁcant inverse correlation with their mRNA levels. Methylation levels were
not associated with KCNJ5 or ATP1A1 mutations in human adrenal samples. We demonstrated an
increased incidence of CpG island demethylation of GPCR-related gene in APA. The expression of two
receptors, HTR4 and PTGER1, showed a strong association with DNA methylation.
© 2017 Elsevier B.V. All rights reserved.
1. Introduction
Primary aldosteronism (PA) is the most frequent cause of sec-
ondary hypertension associated with autonomous excess aldoste-
rone production and secretion (Funder et al., 2016). Patients with
PA have an increased risk of cardiovascular disease compared with
essential hypertensionwith similar blood pressure and risk proﬁles
(Milliez et al., 2005, Mulatero et al., 2013). Therefore, the elucida-
tion of autonomous excess aldosterone productionmachinery leads
to detect therapeutic target for PA, and it is important to improve
health and extend life span.
PA is mainly classiﬁed with aldosterone-producing adenoma
(APA) and idiopathic hyperaldosteronism. APA is a form of sec-
ondary hypertension potentially curable by adrenalectomy (Funder
et al., 2016). Recent research shows that 50e80% of APAs contain
somatic mutations of KCNJ5, ATP1A1, ATP2B3, CACNA1D, or CTNNB1,
resulting in over-production of aldosterone (Akerstrom et al., 2016,
Azizan et al., 2013, Beuschlein et al., 2013, Choi et al., 2011). On the
other hand, it is well known that ectopic or aberrant membrane
receptors such as G protein-coupled receptors (GPCR) are
expressed in APAs and are associated with acceleration or sup-
pression of aldosterone production by agonists or antagonists,
respectively (Duparc et al., 2015, Perraudin et al., 2006, Ye et al.,
2007, Zwermann et al., 2009). The regulation of the membrane
receptor may be a therapeutic target for aldosterone production in
APA. However, the mechanism of ectopic or aberrant membrane
receptor expression in APA has not been elucidated.
Berger et al. deﬁned an epigenetic trait as a stably heritable
phenotype resulting from changes in a chromosome without al-
terations in the DNA sequence (Berger et al., 2009). DNA methyl-
ation is a well-studied epigenetic modiﬁcation that occurs mostly
on the 5-carbon of cytosine residues in CpG dinucleotides. Hypo-
methylation of CpG in the promoter region potentiates gene tran-
scription by facilitating the binding of transcription factors (Sen
et al., 2016). Alteration of DNA methylation can inﬂuence the
development or progression of some disorders including cancer,
adenoma, and life style-related diseases (Maqbool et al., 2016). In
fact, we and others have demonstrated that CYP11B2, the rate-
limiting enzyme for aldosterone production, is demethylated in
APA (Howard et al., 2014, Yoshii et al., 2016). In adrenal tissues, DNA
methylation is likely to be involved in fetal adrenal development
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and adrenocortical cancer progression via its regulation of tran-
scription (Legendre et al., 2016, Slieker et al., 2015).
Taken together, the transcription of GPCR or GPCR-related genes
might be regulated by their DNA methylation in adrenal cells,
however DNA methylation levels of GPCR or GPCR-related genes
has not been studied. Therefore, we hypothesized that the
expression of GPCRs might be regulated by DNA methylation in
adrenal cells. The aims of our study were to clarify the DNA
methylation levels of GPCR or GPCR-related genes in APA and the
effects of DNA methylation on mRNA expression levels in APA.
2. Methods
2.1. Patients and samples
The inclusion criteria for patients and tissue samples have been
described in a previous report (Yoshii et al., 2016). Brieﬂy, the
diagnosis of PA was based on the guidelines of the Japan Endocrine
Society (Nishikawa et al., 2011). PAwas diagnosed if the aldosterone
renin ratio (aldosterone, ng/dL; plasma renin activity, ng/mL/hr)
was greater than 20. The captopril challenge test, furosemide-
upright test, and saline infusion test were performed to conﬁrm
the diagnosis. Adrenal venous sampling was performed for subtype
diagnosis in all patients. Non-functioning adenoma (NFA) was
diagnosed by radiological ﬁndings and endocrinological results
showing cortisol or aldosterone excess as previously reported (Oki
et al., 2012). Twelve NFA and 35 APA samples were obtained by
surgery and stored at !80 "C until used for DNA methylation and
quantitative polymerase chain reaction (qPCR) analysis. The clinical
characteristics of the patients were shown in our previous report
(Yoshii et al., 2016). The genotypes of the APAs included 5 ATP1A1
mutations, 21 KCNJ5mutations, and 9wild types. Five of 12 NFA and
19 of 35 APA samples were used for microarray analysis. This study
was approved by the ethics committee of Hiroshima University, and
written informed consent was obtained from all patients.
2.2. DNA genotyping and methylation analysis
Genomic DNA was extracted from NFA or APA samples by
DNeasy blood and tissue kit (Qiagen, Hilden, Germany). Genotyping
of the adenomas for KCNJ5, ATP1A1, ATP2B3, CACNA1D, and CTNNB1
was performed as previously described (Kishimoto et al., 2016). DNA
methylation levels were determined using the Inﬁnium Human-
Methylation450 BeadChip kit (Illumina, San Diego, CA, USA), as
previously described (Yoshii et al., 2016). Ninty-nine percent of the
RefSeq genes and 96% of the CpG islands were covered. Methylation
levelswere shown as b values, whichwere then used to estimate the
methylated signal intensity (Dedeurwaerder et al., 2011). The
average b values were expressed as 0 to 1, representing completely
non-methylated to completely methylated values, respectively.
2.3. RNA extraction, qPCR assay, and microarray analysis
Total RNA extraction and cDNA synthesis were performed as
previously described (Kishimoto et al., 2016). PCR primers for HTR4
(5-hydroxytryptamine receptor 4),MC2R (melanocortin 2 receptor),
TACR1 (tachykinin receptor 1), GRM3 (glutamate metabotropic re-
ceptor 3), PTGER1 (prostaglandin E receptor 1) and GAPDH (glycer-
aldehyde-3-phosphate dehydrogenase) are shown in Table S1.
Expression levels were assessed using SYBR-green-based gene
expression assays (Takara Bio SYBR Premix EX Taq; Takara Bio Inc.,
Shiga, Japan). Gene expression levels were determined as arbitrary
units normalized against GAPDH expression. Microarray analysis
was performed using the SurePrint G3 Human Gene Expression
8 # 60K v2 array (Agilent Technologies Inc., Santa Clara, CA, USA).
2.4. Statistical analysis
Results were expressed as mean ± S.D. The differences were
considered signiﬁcant at P < 0.05. Analyses were performed using
SPSS forWindows (release 24.0; SPSS Inc., Chicago, IL, USA). First, t-
test was applied for the differences of DNA methylation or mRNA
expression levels by DNA methylation array and transcriptome
analysis, respectively. Signiﬁcantly higher and lower DNA methyl-
ation levels of the genes in APA were denoted as “hyper-methyl-
ation” and “hypo-methylation”, respectively. Signiﬁcantly higher
and lower mRNA expression levels of the genes in APA were
expressed as “up-regulation” and “down-regulation”, respectively.
Second, the expression levels of HTR4, MC2R, TACR1, GRM3, and
PTGER1 mRNA detected by qPCR were analyzed by the t-test after
logarithmic transformation, because they did not ﬁt a normal dis-
tribution. The relationships between DNA methylation and mRNA
expression levels or plasma aldosterone levels were analyzed by
Spearman's test. Finally, differences of DNA methylation levels
among APA genotypes were analyzed by one-way ANOVA followed
by Bonferroni comparisons.
3. Results
3.1. Methylation levels of GPCR or GPCR-related genes in APA
We identiﬁed 192 GPCR or GPCR-related genes from the Gene
Set Enrichment Analysis website (http://www.broadinstitute.org/
gsea/index.jsp). From this list of genes, 185 had as DNA methyl-
ation lesion in the promoter region up to !1500 bases from tran-
scription start site (TSS). Methylation at these sites was compared
between NFAs (n ¼ 12) and APAs (n ¼ 35). APAs showed hypo-
methylation in 66 genes and hypermethylation 14 genes (Table 1
and Table S2). Six genes showed a mixture of hypo- and hyper-
methylation in APAs (Table 1 and Table S2). Ninety-nine genes
showed no differences in DNA methylation between NFAs and
APAs.
3.2. Integration analysis between methylation level and mRNA
expression
Results of the integration study between microarray and
methylation analysis are shown in Table 1.We focused on geneswith
an inverse association between methylation and gene expression,
because this indicates that DNA methylation directly regulates
the expression of these genes. HTR4, MC2R, TACR1, GRM3, and
PTGER1 showed hypomethylation and upregulation ofmRNA inAPAs
(Table 1 and Fig. S1). Nine genes showed higher mRNA expression in
APAs than NFAs (Table S3), but no differences in DNA methylation
between APA and NFA. Thus, some GPCR and GPCR-related genes
Table 1
Relationship between DNA methylation and mRNA expression among GPCR in APA.
mRNA expression in APA
compared with NFA
DNA methylation in APA compared with NFA
Hypo-methylation Mixed Hyper-methylation
up-regulation 5 0 2
not signiﬁcant 61 6 12
down-regulation 0 0 0
A t-test was applied for the differences of DNA methylation or mRNA expression
levels by DNA methylation array and transcriptome analysis. Signiﬁcantly higher
and lower DNA methylation levels of the genes in APA were denoted as “hyper-
methylationis” and “hypo-methylation”, respectively. Signiﬁcantly higher and
lower mRNA expression levels of the genes in APA were expressed as “up-regula-
tion” and “down-regulation”, respectively. The speciﬁc gene symbols were shown in
Table S2. NFA, non-functioning adrenocortical adenoma; APA, aldosterone-
producing adenoma; GPCR, G protein-coupled receptor.
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were highly expressed in APAs compared to NFAs, in agreementwith
previous reports (Duparc et al., 2015, Perraudin et al., 2006, Ye et al.,
2007, Zwermann et al., 2009).
3.3. Relationship between GPCR gene methylation and mRNA levels
We performed qPCR analysis of HTR4, MC2R, TACR1, GRM3, and
PTGER1 gene expression in NFAs (n ¼ 12) and APAs (n ¼ 35). HTR4
expression was 9.3-fold higher (P < 0.001, Fig. 1), and PTGER1
expression was in 6.6-fold higher in APAs than in NFAs (P ¼ 0.003,
Fig. 1). There were no differences in MC2R, TACR1, or GRM3
expression between APAs and NFAs (Fig. 1).
The presumed methylation sites of HTR4 and PTGER1, which had
inverse correlations between DNA methylation and mRNA
expression, are depicted in Fig. 2. HTR4 and PTGER1 had 3 and 4
methylation sites, respectively, in their promoter regions. First, the
methylation levels of HTR4 and PTGER1 were compared between
NFAs and APAs. Two methylation sites !229 bases from the HTR4
gene TSS and !666 bases from the PTGER1 gene TSS were signiﬁ-
cantly hypomethylated in APAs (Table 2). Second, the relationship
between DNA methylation at these sites and mRNA expression
levels were analyzed by Spearman's test. Methylation levels at the
above two sites had a signiﬁcant inverse correlation with mRNA
levels (Table 3). Finally, we analyzed the relationship between DNA
methylation levels and plasma aldosterone levels. However, there
were no correlations between them as shown in Table S4.
3.4. Association of APA genotype and DNA methylation levels of
GPCR genes
DNA methylation levels were compared among APAs with
Fig. 1. mRNA expression levels of the GPCRs, HTR4,MC2R, TACR1, GRM3, and PTGER1, in aldosterone-producing adenoma (APA, n ¼ 35) and non-functioning adrenocortical adenoma
(NFA, n ¼ 12). n.s., not signiﬁcant.
Fig. 2. Conceivable methylation sites of HTR4 (A) and PTGER1 (B) promoters. Gene accession numbers are represented in the parentheses of each heading. The locations from the
transcription start site are indicated as numbers in parentheses.
Table 2
Relationship between HTR4 or PTGER1 methylation levels and their mRNA expres-
sion levels.
DNA methylation
site
Methylation Rate (b value) Fold change
(APA/NFA)
P value
NFA average APA average
HTR4
a 0.58 ± 0.20 0.57 ± 0.14 0.97 0.754
b 0.53 ± 0.19 0.34 ± 0.14 0.65 0.001
c 0.84 ± 0.06 0.83 ± 0.05 0.99 0.628
PTGER1
d 0.72 ± 0.18 0.71 ± 0.13 0.99 0.920
e 0.26 ± 0.04 0.22 ± 0.04 0.82 0.001
f 0.06 ± 0.04 0.07 ± 0.05 1.15 0.561
g 0.06 ± 0.05 0.06 ± 0.08 1.00 0.957
The relationship between HTR4 or PTGER1 methylation levels and their mRNA
expression levels were analyzed by Spearman's test. The methylation sites from “a”
to “g” are shown in Fig. 2. NFA, non-functioning adrenocortical adenoma; APA,
aldosterone producing adenoma.
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ATP1A1 mutation, KCNJ5 mutation, and wild type genotypes. The
methylation levels of site “b” in HTR4, where signiﬁcant correlation
between methylation and mRNA levels were found, did not show
methylation differences among APAs with different genotypes
(Fig. 3A). The methylation levels of site “e” in PTGER1 showed no
difference among APAs with different genotypes (Fig. 3B).
4. Discussion
We demonstrated that 33.8% (65 of 192) of GPCR or GPCR-
related genes were hypo-methylated in the promoter region in
APAs. The integration study of DNA methylation and gene expres-
sion analysis identiﬁed ﬁve genes whose expression might be
directly regulated by DNA methylation, and two genes showed
inverse correlation between DNA methylation and mRNA expres-
sion in adrenal tumors. Methylation levels were not associatedwith
KCNJ5 or ATP1A1 mutation in human adrenal samples.
Our study demonstrated that the promoters of GPCR or GPCR-
related genes are associated with a much higher incidence of CpG
island demethylation in APAs. ACTH, glucagon, somatostatin,
parathyroid hormone and glutamate metabotropic receptors genes,
which were hypomethylation in APAs, have been were associated
with aldosterone production (Ye et al., 2007, Zwermann et al.,
2009). However, there were no differences in expression of these
receptors between NFAs and APAs in our microarray analysis
(Fig. S1). These genes are unlikely to be regulated only by DNA
methylation, because there was no inverse correlation between
DNA methylation and mRNA expression levels in adrenal samples.
They may also be regulated by transcription factors and/or other
epigenetic mechanisms. Importantly, these genes are in a state that
facilitates gene transcription in APAs, and their ectopic or aberrant
expression could lead to further aldosterone production.
We found that the methylation levels of HTR4 and PTGER1 in
APAs are lower than those in NFAs, and thesemethylation levels are
associated with their mRNA levels. Since hypo-methylation of CpG
in the promoter region potentiates gene transcription by facilitating
the binding of transcription factors (Sen et al., 2016), the expression
levels of transcription factors that bind to these regions would not
be different between NFAs and APAs. Therefore, methylation level is
considered a rate-limiting factor for receptor expression. Other-
wise, no or low levels of transcription factors would be present to
bind to these regions in adrenal adenomas. Remarkably, our study
found that two GPCR genes, HTR4 and PTGER1, may be regulated by
DNA methylation state.
HTR4 is serotonin receptor subtype known to be expressed in
the adrenal gland according to human tissue speciﬁc expression
analysis using RNA-seq and proteomics (Fagerberg et al., 2014).
Importantly, HTR4 is up-regulated in APAs and serotonin increases
aldosterone secretion in vivo and in vitro (Duparc et al., 2017, Ye
et al., 2007, Zwermann et al., 2009). Duparc et al. reported that
serotonin secreted from mast cells stimulates aldosterone pro-
duction through paracrine regulation in APAs (Duparc et al., 2015).
Our data indicate that the expression of HTR4 and subsequent
stimulation of aldosterone production in APAs may be regulated by
methylation of the HTR4 gene.
PTGER1 encodes prostaglandin E receptor 1, one of the four re-
ceptors identiﬁed for prostaglandin E2. This is the ﬁrst study to
show up-regulation of PTGER1 in APAs. In adrenal glomerulosa
cells, prostaglandin E2 increased aldosterone production by stim-
ulating the conversion of cholesterol to pregnenolone (Campbell
et al., 1986). A selective agonist for prostaglandin E receptor 1 in-
hibits the up-regulation of aromatase expression following
epidermal growth factor treatment in human adrenocortical car-
cinoma (H295R) cells (Watanabe et al., 2006). Aldosterone induces
vascular inﬂammation via cyclooxygenase-2 expression and acti-
vation which sequentially produce prostaglandin E2 (Yoshimoto
and Hirata, 2007), and thus PTGER1 up-regulation may lead to
further aldosterone production in APAs. Taken together, APAs have
high expression of PTGER1 which might be regulated by DNA
methylation, and the expression might induce aldosterone over-
production and tumor progression in APAs.
There were no correlations between DNA methylation levels of
GPCR or GPCR-related genes and plasma aldosterone levels. The
methylation levels would determine their expression levels to
collaborate with transcription factors (Sen et al., 2016). In addition,
aldosterone levels were determined by the receptor expression
levels and the plasma ligand levels. Therefore, in analyzing together
with transcription levels and ligand levels, we could predict the
Table 3
Relationship between HTR4 or PTGER1 methylation levels and their mRNA expres-
sion levels.
DNA methylation site r P value
HTR4
a 0.057 0.702
b !0.336 0.021
c 0.030 0.842
PTGER1
d !0.112 0.455
e !0.353 0.015
f !0.208 0.161
g !0.091 0.545
The relationship between HTR4 or PTGER1 methylation levels and their mRNA
expression levels were analyzed by Spearman's test. The methylation sites from a to
g are shown in Fig. 2.
Fig. 3. Difference in HTR4 and PTGER1 methylation levels among genotypes of aldosterone-producing adenomas (APA). (A) The methylation levels of site “b” in HTR4 among
different APA genotype are shown. Methylation values for ATP1A1 (n ¼ 5), KCNJ5 (n ¼ 21), and wild type (WT, n ¼ 9) were 0.25 ± 0.12, 0.35 ± 0.12, and 0.37 ± 0.16, respectively. (B)
The methylation levels of site “e” in PTGER1 among APA genotype are shown. Methylation values for ATP1A1, KCNJ5, and WT were 0.19 ± 0.03, 0.22 ± 0.04, and 0.22 ± 0.04,
respectively.
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plasma aldosterone levels related with DNA methylation levels of
GPCR or GPCR-related genes. As mentioned above, these genes are
in a state that facilitates gene transcription to produce more aldo-
sterone in APAs.
Some GPCR or GPCR-related genes may be regulated by intra-
cellular signaling, but not by DNA methylation. GNRHR and LHCGR
are well known to be highly expressed in APAs (Ye et al., 2007,
Zwermann et al., 2009), but their methylation levels were not
different between NFAs and APAs (data not shown). We have pre-
viously reported that GNRHR and LHCGR are regulated by a KCNJ5
mutation that induces the activation of intracellular calcium
signaling (Kishimoto et al., 2016). Therefore, it is thought that the
regulation of some ectopic or aberrant receptors is independent of
DNA methylation state in APAs.
This study reports a comprehensive integration analysis of DNA
methylation and mRNA expression related to GPCR in APAs. We
demonstrated that GPCR or GPCR-related genes had a much higher
incidence of CpG island demethylation in APAs, and due to this
demethylation, some receptors were in a state that would facilitate
gene transcription. The expression of two receptors, HTR4 and
PTGER1, had a strong association with DNA methylation; further-
more, increased HTR4 expression may stimulate aldosterone pro-
duction in APAs. This study provides important information
regarding the molecular mechanisms of ectopic or aberrant re-
ceptor expression in APAs and identiﬁes therapeutic or diagnostic
targets that could be studied further.
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